Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F. Wood JM, et al. Among authors: buchdunger e. Cancer Res. 2000 Apr 15;60(8):2178-89. Cancer Res. 2000. PMID: 10786682
Pharmacology of imatinib (STI571).
Buchdunger E, O'Reilly T, Wood J. Buchdunger E, et al. Eur J Cancer. 2002 Sep;38 Suppl 5:S28-36. doi: 10.1016/s0959-8049(02)80600-1. Eur J Cancer. 2002. PMID: 12528770 Review.
A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo.
Lydon NB, Mett H, Mueller M, Becker M, Cozens RM, Stover D, Daniels D, Traxler P, Buchdunger E. Lydon NB, et al. Among authors: buchdunger e. Int J Cancer. 1998 Mar 30;76(1):154-63. doi: 10.1002/(sici)1097-0215(19980330)76:1<154::aid-ijc24>3.0.co;2-b. Int J Cancer. 1998. Retraction in: Int J Cancer. 1999 May 17;81(4):669. doi: 10.1002/(sici)1097-0215(19990517)81:4<669::aid-ijc27>3.0.co;2-c PMID: 9533776 Retracted.
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.
Bold G, Altmann KH, Frei J, Lang M, Manley PW, Traxler P, Wietfeld B, Brüggen J, Buchdunger E, Cozens R, Ferrari S, Furet P, Hofmann F, Martiny-Baron G, Mestan J, Rösel J, Sills M, Stover D, Acemoglu F, Boss E, Emmenegger R, Lässer L, Masso E, Roth R, Schlachter C, Vetterli W. Bold G, et al. Among authors: buchdunger e. J Med Chem. 2000 Jun 15;43(12):2310-23. doi: 10.1021/jm9909443. J Med Chem. 2000. PMID: 10882357
Tyrosine kinase inhibitors: from rational design to clinical trials.
Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J. Traxler P, et al. Among authors: buchdunger e. Med Res Rev. 2001 Nov;21(6):499-512. doi: 10.1002/med.1022. Med Res Rev. 2001. PMID: 11607931 Review.
Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Regenass U, Lydon NB. Buchdunger E, et al. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2558-62. doi: 10.1073/pnas.92.7.2558. Proc Natl Acad Sci U S A. 1995. Retraction in: Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):12069. doi: 10.1073/pnas.95.20.12069-a PMID: 7708684 Free PMC article. Retracted.
64 results